Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Background. Nonalcoholic fatty liver disease (NAFLD) is commonly observed in patients with type 2 diabetes (T2D). Semaglutide, a glucagon-like peptide 1 receptor agonist, may have a therapeutic role by targeting common mechanisms involved in the pathophysiology of T2D and NAFLD. The study aimed to assess the effectiveness of Semaglutide on NAFLD in patients with T2D. Methods. Forty-eight patients were treated with subcutaneous Semaglutide in add-on to metformin for 52 weeks. After the baseline visit (T0), follow-up was scheduled quarterly (T3, and T6) and then at 12 months of therapy (T12). During each visit, body composition was analyzed by phase-sensitive bio-impedance, and NAFLD was diagnosed and staged by Ultrasound (US) imaging. Surrogate biomarkers of NAFLD were also calculated and followed over time. Results. A significant decrease in anthropometric and glucometabolic parameters, insulin resistance, liver enzymes, and laboratory indices of hepatic steatosis was observed during treatment. Similarly, fat mass and visceral adipose tissue (VAT) decreased over time more than skeletal muscle and free-fat mass. US-assessed VAT thickness and the 12-point steatosis score also declined at T3 up to T12. Liver steatosis improved in most patients (70%), showing a reduction by at least one class in the semiquantitative US staging. Conclusion. Besides glucose control and body composition improvements, Semaglutide was effective in ameliorating the clinical appearance and severity of NAFLD in T2D patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data are very limited for the highest dose of Semaglutide (2.4 mg), as most studies have focused on the 1 mg dose. 8 , 9 , 10 , 11”
From Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study (2026) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“GLP-1 RAs, particularly semaglutide, have been shown to reduce liver steatosis and improve markers of liver inflammation and fibrosis in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease.34, 35, 36”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Semaglutide is one of the most potent GLP-1 RAs, as demonstrated by its beneficial effects on glucose control [24,25], CV and renal protection [26,27], weight loss, and improving body composition [28].”
BackgroundEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286 · cited 15×
“Abbreviations NAFLD NonAlcoholic Fatty Liver Disease T2D Type 2 Diabetes IR Insulin Resistance HDL High Density Lipoproteins NASH NonAlcoholic Steatohepatitis MAFLD Metabolic Associated Fatty Liver Disease CV Cardiovascular SMM Skeletal Muscle Mass VAT Visceral Adipose Tissue GLP-1 RAs Glucagon-Like Peptide-1 Receptor…”
BackgroundInfluentialBedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042 · cited 1×
“3) was highly indicative of liver steatosis [31].”
BackgroundRoberts, H. C., Denison, H. J., Martin, H. J., Patel, H. P., Syddall, H., Cooper, C., & Sayer, A. A. (2011) · Age and Ageing · doi:10.1093/ageing/afr051 · Cited by 3,001 · cited 1×
“The hand grip (HG) strength test was performed using a manual hydraulic dynamometer (Lafayette Instrument, Lafayette, IN, USA) to assess the muscle strength in both hands [33].”
MethodA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“4 mg) for 72 consecutive weeks, showing promising effects on intrahepatic fat accumulation but without significant changes in terms of liver fibrosis compared to placebo [43].”
BackgroundGlobal epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease
Lee, J.-H., Kim, D., Kim, H. J., Lee, C.-H., Yang, J. I., Kim, W., Kim, Y. J., Yoon, J.-H., Cho, S.-H., Sung, M.-W., et al. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.08.002 · Cited by 1,621 · cited 1×
“A value over 36 was indicative of NAFLD and a value lower than 30 should exclude it [30].”
BackgroundHamaguchi, M., Kojima, T., Itoh, Y., Harano, Y., Fujii, K., Nakajima, T., Kato, T., Takeda, N., Okuda, J., Ida, K., et al. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01526.x · Cited by 906 · cited 1×
“Moreover, in order to observe minimal variations in steatosis during treatment, the Hamaguchi 6-point score [36] was modified to obtain a more detailed ultrasound liver steatosis score (US-LSS), ranging from 0 to 12 points (Table 1).”
MethodThe Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Utzschneider, K. M., & Kahn, S. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0587 · Cited by 856 · cited 1×
“Insulin resistance induces an imbalance between lipid production and disposal, leading to lipid accumulation in hepatocytes, chronic low-grade inflammation, progression to NASH, and adverse hepatic and extrahepatic outcomes [11].”
Background
Cited by
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
“36 In the recent ESSENCE trial, 62.9% of patients receiving semaglutide achieved resolution of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis at 72 weeks, compared to 34.3% in the placebo group (estimated treatment difference [ETD]: 28.7%, 95% CI 21.1, 36.2).”
InfluentialLocatelli, J. C., Costa, J. G., Haynes, A., Naylor, L. H., Fegan, P. G., Yeap, B. B., & Green, D. J. (2024) · Diabetes Care · doi:10.2337/dci23-0100 · Cited by 152
Semaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Bandyopadhyay, S., Das, S., Samajdar, S. S., & Joshi, S. R. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102849 · Cited by 64
Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Lavarra, V., Triggiani, D., Crudele, L., Triggiani, V., Sabbà, C., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1240263 · Cited by 73
Self-citationAlissou, M., Demangeat, T., Folope, V., Van Elslande, H., Lelandais, H., Blanchemaison, J., Cailleaux, P., Guney, S., Aupetit, A., Aubourg, A., et al. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70141 · Cited by 72
Agius, R., Pace, N. P., & Fava, S. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3725 · Cited by 74
“264 268–270 FGF21 is also being proposed as a potential novel therapeutic modality, especially with regard to improving hepatic steatosis.”
BackgroundLee, H. A., & Kim, H. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119324 · Cited by 48
“(Italy) [45] Uncontrolled T2DM and NAFLD Semaglutide 0.”
BackgroundEffects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study
Ditzenberger, G. L., Lake, J. E., Kitch, D. W., Kantor, A., Muthupillai, R., Moser, C., Belaunzaran-Zamudio, P. F., Brown, T. T., Corey, K., Landay, A. L., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciae384 · Cited by 44
Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
Lisco, G., De Tullio, A., Disoteo, O., Piazzolla, G., Guastamacchia, E., Sabbà, C., De Geronimo, V., Papini, E., & Triggiani, V. (2023) · Endocrine Connections · doi:10.1530/ec-23-0257 · Cited by 37
Self-citationPantanetti, P., Cangelosi, G., Alberti, S., Marco, S. D., Michetti, G., Cerasoli, G., Giacinti, M. D., Coacci, S., Francucci, N., Petrelli, F., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1394506 · Cited by 52
Anyiam, O., Ardavani, A., Rashid, R. S. A., Panesar, A., & IDRIS, I. R. (2025) · Obesity Reviews · doi:10.1111/obr.13916 · Cited by 49
Li, M., Cui, M., Li, G., Liu, Y., Xu, Y., Eftekhar, S. P., & Ala, M. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2266-1503 · Cited by 37
“…the promising results of these clinical trials imply that it is not always necessary to identify new therapeutic targets to achieve satisfactory clinical outcomes, and simultaneous targeting of a combination of already-known mechanisms can provide a greater benefit in most cases [12, 13, 17– 20].”
Nelson, L. W., Lee, M. H., Garrett, J. W., Pickhardt, S. G., Warner, J. D., Summers, R. M., & Pickhardt, P. J. (2024) · American Journal of Roentgenology · doi:10.2214/ajr.24.31805 · Cited by 35
Añazco, D., & Acosta, A. J. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01599-z · Cited by 43
“…of incretin-based therapies for obesity management has revolutionized the fi eld of obesity medicine, with newer medications being able to induce clinically signi fi cant weight loss [20, 21], while also achieving an improvement in comorbidities [22] and reduction in cardiovascular mortality [23].”
Luo, Z.-Y., Li, X., Chen, C.-T., Kang, H.-H., Zhang, Z., Wang, D., & Gong, J. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2419989 · Cited by 36
Ros-Madrid, I., Cano-Mármol, R. P., Ferrer-Gomez, M., & Ramos-Molina, B. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0148 · Cited by 31
Konings, L. A. M., Matute, L. M., Boeren, A. M. P., van de Luitgaarden, I. A. T., Dirksmeier-Harinck, F., de Knegt, R. J., Tushuizen, M. E., Grobbee, D. E., Holleboom, A. G., & Cabezas, M. C. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70003 · Cited by 34
The effect of obesity pharmacotherapy on body composition, including muscle mass
Argyrakopoulou, G., Gitsi, E., Konstantinidou, S. K., & Kokkinos, A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01533-3 · Cited by 28
“Furthermore, liver steatosis showed improvement in a substantial majority of patients (70%), with a reduction by at least one class according to the semiquantitative ultrasound staging [49].”
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases
Tsutsumi, T., Nakano, D., Hashida, R., Sano, T., Kawaguchi, M., Amano, K., & Kawaguchi, T. (2023) · Nutrients · doi:10.3390/nu15051123 · Cited by 31
“appearance and severity of NAFLD, such as hepatic steatosis index and AST to platelet ratio index for DM-MAFLD, in addition to improving glycemic control including homeostatic model assessment for insulin resistance index, fat mass, and visceral adipose tissue [18].”
MethodRecent advances in peptide-based therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171149 · Cited by 25
Volpe, S., Vozza, A., Lisco, G., Fanelli, M., Racaniello, D., Bergamasco, A., Triggiani, D., Pierangeli, G., Pergola, G. D., Tortorella, C., et al. (2024) · Nutrients · doi:10.3390/nu16223841 · Cited by 27
Self-citationMechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?
Ezhilarasan, D. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17037 · Cited by 28
“A once-weekly escalating s.c. dose of semaglutide for 52 weeks in NAFLD patients with T2DM improved IR, transaminases, and hepatic steatosis (in 70% of patients), with a significant decrease in fat mass and visceral adipose tissue [68].”
Kimura, T., Katakura, Y., Shimoda, M., Kawasaki, F., Yamabe, M., Tatsumi, F., Matsuki, M., Iwamoto, Y., Anno, T., Fushimi, Y., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15258 · Cited by 28
“29,30 To the best of our knowledge, there are no prospective comparative reports on the effects of dulaglutide and semaglutide on liver fat percentage at doses approved in Japan.”
BackgroundGad, A. I., Ibrahim, N. F., Almadani, N. A., Mahfouz, R., Nofal, H. A. E., Elrafey, D. S., Ali, H. T., Elhawary, A. T., & Sadek, A. M. E. M. (2024) · Diseases · doi:10.3390/diseases12080186 · Cited by 23
“as it a . loss, and their cell of ]. aminotrans-ferases semaglu-tide or doses is of nearly between study groups, which is a comparable percentage of moderate fatty liver infiltration of 44% reported by Volpe et al. [35].”
BackgroundResultInfluentialHuang, Y., Liao, J., & Liu, Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1222636 · Cited by 19
“Therapeutics for patients with T2DM or other dysmetabolic conditions may affect the body composition, for example, the muscle strength and the muscle quality index (37).”
BackgroundKorakas, E., Kountouri, A., Pavlidis, G., Oikonomou, E., Vrentzos, E., Michalopoulou, E., Tsigkou, V., Katogiannis, K., Pliouta, L., Balampanis, K., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae122 · Cited by 18
“In the study by Volpe et al [36], who enrolled a very similar cohort to ours, semaglutide 0.5 mg for 52 weeks led to at least 1-class reduction in the 4-point semiquantitative staging in NAFLD diagnosed via ultrasound, along with the expected improvements in liver enzymes, glycemic control, and…”
MethodInfluentialScavo, M. P., Lisco, G., Depalo, N., Rizzi, F. R., Volpe, S., Arrè, V., Carrieri, L., Notarnicola, M., Nunzio, V. D., Curri, M. L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031493 · Cited by 19
“In total, 48 patients with type 2 diabetes and clinically established MASLD were treated with once-weekly subcutaneous semaglutide for 52 weeks, as described elsewhere [17].”
MethodSelf-citationSawicka‐Gutaj, N., Gruszczyński, D., Nijakowski, K., Derwich-Rudowicz, A., Krenz, M., Kumar, A. A., Lu, P.-Y., & Ruchała, M. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02088-1 · Cited by 24
Lin, Y., Zhang, Z., Zhong, J.-Q., Wang, Z., Peng, Y.-T., Lin, Y.-M., Zhang, H.-P., & Tian, J.-Q. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302155 · Cited by 19
“Further, a real-world investigation has demonstrated that semaglutide can improve liver steatosis in patients with T2DM [14].”
BackgroundTsamos, G., Vasdeki, D., Koufakis, T., Michou, V., Makedou, K., & Tzimagiorgis, G. (2023) · Metabolites · doi:10.3390/metabo13040517 · Cited by 16
Potential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow?
Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01506-1 · Cited by 16
“In another study, semaglutide added to metformin improved NAFLD (diagnosed and staged by ultrasound imaging) in subjects with T2DM after 52 weeks of treatment [11].”
Kadowaki, T., Nishida, T., Ogawa, W., Overvad, M., Tobe, K., & Yamauchi, T. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.03.003 · Cited by 15
Impact of Incretin-Based Therapy on Skeletal Muscle Health
Koceva, A., Janež, A., & Jensterle, M. (2025) · Medicina · doi:10.3390/medicina61091691 · Cited by 16
“Both hand grip strength and muscle quality index remained unchanged [59].”
White adipose tissue in type 2 diabetes and the effect of antidiabetic drugs
Zhao, Y., & Yue, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01678-9 · Cited by 15
“…study revealed that adding semaglutide to metformin treatment, starting with a weekly subcutaneous injection of 0.25 mg for one month, then increasing to 0.5 mg, and further to 1 mg after six months, significantly reduced VAT and liver steatosis in patients with T2D after 52 weeks [166].”
InfluentialVozza, A., Triggiani, D., Fanelli, M., Lisco, G., Coletto, D., Custodero, C., Volpe, S., Racaniello, D., Colaianni, V., Lavarra, V., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1674308 · Cited by 12
Self-citationEvolving role of semaglutide in NAFLD: in combination, weekly and oral administration
Koureta, E., & Cholongitas, Ε. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1343587 · Cited by 15
Beyond fat: Does semaglutide affect lean mass?
Jamialahmadi, T., Eid, A. H., Gadde, K. M., Almahmeed, W. A., Kroh, M., Zein, M. A., & Sahebkar, A. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.12.004 · Cited by 15
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 15
The expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 11
“These findings were complemented by decreases in hepatic and adipose tissue metrics, such as the fat mass index (FMI) and vascular adi - pose tissue (BIA-VAT), highlighting semaglutide’s broader metabolic benefits [ 122 ].”
Perioperative Considerations for Patients on Semaglutide
Pai, S., Smith, M. A., Beam, W. B., & Harbell, M. W. (2024) · Current anesthesiology reports · doi:10.1007/s40140-024-00611-6 · Cited by 10
Cazac, G.-D., Lăcătușu, C.-M., Ștefănescu, G., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2023) · Metabolites · doi:10.3390/metabo13050581 · Cited by 10
“The reduction of liver fat content was assessed by either ultrasound [45,56,59,69] or magneticresonance-based imaging methods [43,64,72].”
MethodInfluentialLiang, D., Zhang, J., Li, L., Li, Y., Xu, L., & Wu, H. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1403720 · Cited by 11
Repurposing of semaglutide by targeting SIRT1 and TGF‐β/Smad signaling in hepatic fibrosis
Hawary, O. A., Wadie, W., El-Said, Y. A. M., & Hassan, O. F. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04675-x · Cited by 11
“Recent research has shown that SEMA improves liver biomarkers in patients with T2DM (Chen et al. 2022) and reduces the severity of non-alcoholic fatty liver disease (NAFLD) and liver damage (Volpe et al. 2022).”
Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review
Alfawaz, S. A., Burzangi, A. S., & Esmat, A. (2024) · Cureus · doi:10.7759/cureus.67080 · Cited by 16
Caballero Mateos, I., García de Lucas, M. D., Doulatram-Gamgaram, V. K., Moreno-Moreno, P., Jimenez-Millan, A. I., Botana-López, M., Merino-Torres, J. F., Soto-Gónzalez, A., Fernández-García, J. C., & Morales-Portillo, C. (2024) · Nutrients · doi:10.3390/nu16152545 · Cited by 8
Yendewa, G. A., Khazan, A., & Jacobson, J. M. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae014 · Cited by 9
“However, the review included only 2 clinical trials with a small number of participants and a high risk of bias [51, 52].”
Backgroundvan Dijk, A. M., de Vries, M., El-Morabit, F., Bac, S. T., Mundt, M. W., van der Schuit, L. E., Hirdes, M. M., Kara, M., de Bruijne, J., van Meer, S., et al. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03417-2 · Cited by 7
Memaj, P., Ouzerara, Z., & Jornayvaz, F. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411271 · Cited by 7
“To that mat- ter, some potential molecules such as GLP-1 receptor agonists, used to treat T2D, or other molecules have yet to be further studied in order to judge their efficiency on NAFLD/NASH. i r l and actions of CEACAM1 as well as f ctors influencing the functio ing of CEACAM1.”
BackgroundInfluentialIncretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease
Muzurović, E. M., Haluzík, M., Horváth, L., Vlacho, B., & Mauricio, D. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128378484250619080753 · Cited by 5
Albor, C., Anyiam, O., Boyle, L., Makaronidis, J., Tan, R. J. L., Iftikhar, S., Burzić, A., Lajeunesse‐Trempe, F., Stanley, M., Bhatti, A. I., et al. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00707-6 · Cited by 5
Iorra, F. D. Q., Jayakar, T., Yee, M. S., Thursz, M. R., Schaan, B. D., & Manousou, P. (2026) · Liver International · doi:10.1111/liv.70643 · Cited by 9
“Baseline strength values in the included studies—such as mean HGS ranging from 30.8 to 33.6 kg [31, 32] and a mean 5-times STS time of 12.5 s [33]—generally exceed established clinical cutoffs for sarcopenia (e.g., HGS < 27 kg for men and < 16 kg for women, or STS > 15 s) [14].”
InfluentialPetralli, G., Zoppo, A. D., Rovera, C., Raggi, F., Salvati, A., Moriconi, D., Distaso, M., Brunetto, M. R., & Solini, A. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02466-7 · Cited by 3
Koullias, E., Papavdi, M., Athanasopoulos, S., Mitrakou, A., Deutsch, M. J., Zoumpoulis, P. S., Manesis, E. K., Thanopoulou, A. C., & Koskinas, J. S. (2024) · Cureus · doi:10.7759/cureus.53813 · Cited by 4
“Additionally, promising results were observed by Volpe et al., who monitored patients receiving Semaglutide for a year, utilizing several biochemical markers and scores, as well as ultrasonography [26].”
Lisco, G., Tullio, A. D., Zupo, R., Prete, M., Piazzolla, G., Racanelli, V., & Triggiani, V. (2025) · Immunologic Research · doi:10.1007/s12026-025-09655-0 · Cited by 4
Self-citationLuo, C., Yu, X. F., Hua, L.-Y., Zeng, M.-Q., Xu, H., Duan, C., Xu, S., Da Yu, S. U. N., Ye, L., & He, D. (2025) · World Journal of Stem Cells · doi:10.4252/wjsc.v17.i11.111162 · Cited by 7
Perioperative Considerations for Patients on GLP1 Agonists
VanderWielen, B. A., & Beam, W. B. (2024) · Advances in Anesthesia · doi:10.1016/j.aan.2024.07.002 · Cited by 3
Guido, D., Cerabino, N., Chito, M. D., Stasi, V. D., Nucci, S. D., Shahini, E., Giannuzzi, V., Cozzolongo, R., Coletta, S., Stabile, D., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111911 · Cited by 4
Saghazadeh, A., Dolatshahi, M., Mohammadi, S., Kasani, S. H., Naghashzadeh, M., Ippolito, J. E., Sirlin, C. B., Mittendorfer, B., Brier, M. R., Schindler, S. E., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70108 · Cited by 3
“[26, 27], CT in four studies (22.2”
InfluentialTapper, E. B., Ryan, T., Zeng, N., Carter, R., Winer-Jones, J. P., Bonafede, M., & Kim, Y. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0223 · Cited by 2
Post-Transplant Hepatic Steatosis: A Condition Not to Overlook
Razzak, I. A., Curry, M. P., Lai, M., & Trivedi, H. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237340 · Cited by 3
“Newer medications, like glucagon-like peptide 1 (GLP-1) agonists, have shown promising results and have led to significant weight loss, improvement in liver transaminases, and steatosis stage when studied in non-transplant patients with NAFLD but are not yet approved [19].”
BackgroundLisco, G., Jo, H.-G., & Colaianni, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1540942 · Cited by 4
Self-citationBerg, E. V., Moftah, S., Yuzbashian, E., & Chan, C. B. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.09.020 · Cited by 1
“…glucagon-like peptide-1 agonists, which show promise in mitigating the progression of MASLD, reducing body weight, and enhancing lipid oxidation in humans [11,12], whereas peroxisome proliferator-activated receptor α and γ (PPAR α / γ ) agonists also reduce hepatic steatosis and fibrosis [13].”
Sato, K., Irie, Y., Asai, H., Yoshioka, S., Murakawa, K., Sho, H., Inui, R., Kosugi, M., Hazama, Y., & Yasuda, T. (2025) · Internal Medicine · doi:10.2169/internalmedicine.6239-25 · Cited by 1
Yu, X., Jia, S., & Shen, D. (2026) · BIO Web of Conferences · doi:10.1051/bioconf/202623702005 · Cited by 1
Peng, T., Lin, H., Tseng, T., Wu, T., & Chao, Y. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70629 · Cited by 2
Jagasia, K., Pfeiffer, A. M., & Vitale, K. (2026) · Journal of Aging Research and Lifestyle · doi:10.1016/j.jarlif.2026.100083 · Cited by 2
“Among the included studies, while all subcutaneous semaglutide studies used standard titration schedules starting at 0.25 mg weekly, five studies[35,36,41,44,49]. titrated to a maximum dose of 1.0 mg (recommended for T2DM), two studies [34,50]. titrated to a maximum dose of 2.4 mg (recommended for…”
InfluentialMenezes, M. L. L., Chiappa, M. E. G., Fuentes-Kloss, R., Tuesta, M., Santos, P., Filho, A. S. S., & Chiappa, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71220 · Cited by 1
“[ 32 ] w a s e x t r a c t e d a s e x p l o r a t o r y f u n c t i o n a l c o n t e x t a n d w a s n o t t r e a t e d a s a s e p a r a t e p oo l e d d o m a i n .”
Machado, L. G., Schmidt, P. H. S., Petroski, G. T., Costa, G. L. L., Ribeiro, L., da Cruz, J. V. R., Canto, G. D. L., Hohl, A., Ronsoni, M. F., & van de Sande‐Lee, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71432 · Cited by 2
(2023) · DHR Proceedings · doi:10.47488/dhrp.v3is2.96 · Cited by 1
Investigating incretins: a review of the use of GLP-1 and GIP receptor agonists for weight loss
Miller, A. (2024) · Journal of Aesthetic Nursing · doi:10.12968/joan.2024.13.1.6
A Precision Medicine Approach for Obesity Management
Añazco, D., Feris, F., Fansa, S., Espinosa, M. A., & Acosta, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-72309-4_15
Metabolic Dysfunction-Associated Steatotic Liver Disease: An Overview of Pharmacotherapy
Hussein, M. T. E., & Favell, D. (2025) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105273
Diversity of pleiotropic effects of semaglutide: From potential mechanisms to real clinical outcomes
Demidova, T. Y., Izmaylova, M. Y., & Shirnina, M. E. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-1-03
Anyiam, O. (2025) · Nottingham ePrints (University of Nottingham) · Cited by 1
Semaglutida y enfermedad hepática grasa asociada a disfunción metabólica: una revisión sistemática
Masson, W. M., Solís, C., & Nogueira, J. P. (2026) · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana · doi:10.52787/agl.v56i1.591
Rôle des cellules de Kupffer dans la physiopathologie des hépatites aiguës
Chabat-Courrède, C. (2024) · theses.fr (ABES) · doi:10.70675/68752933z5f36z44e9z866az70f7363a7e98
Faheem, M. S. B., Cheema, S., Anwar, A., Rafay-ur-Rehman, M., Farhan, K., Mazhar, I., Shahid, H., Khan, F. U., Faheem, M. S. B., Usman, M., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9176897/v1
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
“…2.4 mg was associated with steatohepatitis resolution without worsening of fibrosis in approximately two-thirds of treated patients, compared with roughly one-third in placebo groups at 72 weeks, supporting a clinically meaningful histologic effect beyond isolated biochemical improvement [130–132].”
InfluentialKhan, S. H., Jamal, A., Qadri, M., Zai, I. A., Shah, A., Ahmed, A., Khalid, A. A., Khan, A., Misbahuddin, F., Iftikhar, H., et al. (2026) · Medicine · doi:10.1097/md.0000000000049916
Puskasová, K., Godula, B. J., Samiec, J., Jiravský, O., Szotkowska, V., Kantor, M., Wrobel, J., Jakubovicova, E., Rucki, S., Mohr, J. A., et al. (2026) · Blood Pressure · doi:10.1080/08037051.2026.2701515
Ma, Z., Zhang, X., Leng, Y., & Chen, X. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1954630
“GLP-1 receptor agonists and related multi-receptor agonists can reduce body weight and liver fat (121, 131 – 133), and selected agents improve MASH-related outcomes (132, 134).”
Knapik, J., Fic, W., & Polak-Szczybyło, E. (2026) · Nutrients · doi:10.3390/nu18193247
“Although a modest reduction in skeletal muscle mass has also been reported, this decline appears to stabilize over time [59–64].”
InfluentialFunctional Implications of GLP-1RA Use Beyond Obesity in Aging Adults
Mascone, S. E., Prior, S. J., & Addison, O. R. (2026) · Current Geriatrics Reports · doi:10.1007/s13670-026-00467-0
“[29]) or compared results across sex (Butler et al. [9] and Volpe et al. [25] found results were consistent between sexes).”
Metadata
- Authors
- Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Triggiani, D., Donghia, R., Crudele, L., Rinaldi, R., Sabbà, C., Triggiani, V., De Pergola, G., & Piazzolla, G.
- Affiliations
- University of Bari Aldo Moro (IT)
- Gastroenterology Hospital "Saverio de Bellis" (IT)
- National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Castellana Grotte, Via Turi 27, 70013 Bari, Italy
- Corresponding author
- Piazzolla, Giuseppina
- ORCID
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2022-11-04
- Volume
- 14
- Issue
- 21
- Pages
- 4673
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC9657108
- OpenAlex
- W4308720508
- Cited by
- 84
- References
- 46
- Citations by year
- 2026: 16 · 2025: 23 · 2024: 27 · 2023: 18
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, non-alcoholic fatty liver disease, type 2 diabetes, GLP-1 receptor agonists, hepatic steatosis, visceral adipose tissue, body composition, insulin resistance, metformin add-on therapy, real-world effectiveness
- MeSH terms
- Semaglutide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Prospective Studies, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.